In Ongoing Suit, Alnylam Claims Partner Tekmira Misappropriated Trade Secrets

Alnylam charged Tekmira with wrongly using trade secrets to bolster its own drug delivery technology-development efforts and to file a patent application on Alnylam's phase I liver cancer drug.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.